文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病自体造血干细胞移植后多次小剂量输注G-CSF动员的单倍体淋巴细胞

Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2024-07-07

这项回顾性研究分析106例接受自体造血干细胞移植的急性髓系白血病患者,评估多次小剂量输注粒细胞集落刺激因子动员的单倍体淋巴细胞作为移植后维持治疗的影响。50例接受淋巴细胞维持治疗,21例接受替代维持治疗,35例未接受维持治疗。接受淋巴细胞维持治疗的患者总生存和无病生存显著高于未接受维持治疗者,4年总生存率和无病生存率明显升高。三组复发率无显著差异,但淋巴细胞维持治疗对中危AML患者特别有益,其总生存率和无病生存率显著更高、复发率更低。

要点

  • 淋巴细胞维持治疗组总生存和无病生存显著高于未维持治疗组。
  • 三组复发率无显著差异。
  • 中危AML患者从淋巴细胞维持治疗中获益最明显。

核心结论

  • 多次小剂量输注G-CSF动员的单倍体淋巴细胞可能为自体造血干细胞移植后的AML患者带来良好结局,尤其对中危患者。

研究设计与样本

  • 回顾性研究,分析106例接受自体造血干细胞移植的急性髓系白血病患者。
  • 50例接受淋巴细胞维持治疗,21例接受替代维持治疗,35例未接受维持治疗。

主要发现

  • 接受淋巴细胞维持治疗的患者总生存和无病生存显著高于未接受维持治疗者,4年总生存率和无病生存率明显升高。
  • 三组复发率无显著差异。
  • 中危AML患者中,淋巴细胞维持治疗组总生存率和无病生存率显著更高、复发率更低,优于替代维持治疗组和未维持治疗组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This retrospective study analysed 106 acute myeloid leukaemia (AML) patients undergoing autologous haematopoietic stem cell transplantation (ASCT) to assess the impact of multiple small-dose infusions of granulocyte-colony-stimulating factor (G-CSF)-mobilized haploidentical lymphocytes as post-ASCT maintenance therapy. Among them, 50 patients received lymphocyte maintenance therapy, 21 received alternative maintenance therapy, and 35 received no maintenance therapy. Patients receiving lymphocyte maintenance therapy demonstrated significantly higher overall survival (OS) and disease-free survival (DFS) compared to those without maintenance therapy, with 4-year OS and DFS rates notably elevated. While there were no significant differences in recurrence rates among the three groups, lymphocyte maintenance therapy showcased particular benefits for intermediate-risk AML patients, yielding significantly higher OS and DFS rates and lower relapse rates compared to alternative maintenance therapy and no maintenance therapy. The study suggests that multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes may offer promising outcomes for AML patients after ASCT, particularly for those classified as intermediate-risk. These findings underscore the potential efficacy of lymphocyte maintenance therapy in reducing disease relapse and improving long-term prognosis in this patient population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yang F, Ren Q, Zu Y, et al. Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia. Br J Haematol. 2024. PMID: 38972835. doi:10.1111/bjh.19597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。